Breaking News Instant updates and real-time market news.

BNIX

Bannix Acquisition

/

+

10:51
09/10/21
09/10
10:51
09/10/21
10:51

Bannix Acquisition opens at $10.06, IPO priced at $10 per share

Bannix Acquisition Corp., a newly organized blank check company incorporated as a Delaware corporation, priced its upsized initial public offering of 6M units at an offering price of $10.00 per unit, with each unit consisting of one share of the common stock of the company, one redeemable warrant and one right to receive 1/10 of one share of common stock upon consummation of a business combination. Each warrant will entitle the holder thereof to purchase one share of common stock at $11.50 per share. The units are expected to trade on the Nasdaq Capital Market under the ticker symbol "BNIXU." Once the securities comprising the units begin separate trading, the common stock, the warrants and the rights are expected to be traded on Nasdaq under the symbols "BNIX," "BNIXW" and "BNIXR" respectively. I-Bankers Securities is acting as sole underwriter for the offering.

OTHER BREAKING NEWS FROM THE FLY

Downgrade
CIFI Holdings downgraded to Neutral from Overweight at JPMorgan » 20:31
08/14/22
08/14
20:31
08/14/22
20:31
CFFHF

CIFI Holdings

/

+

JPMorgan analyst Karl…

JPMorgan analyst Karl Chan downgraded CIFI Holdings to Neutral from Overweight with a HK$2.10 price target.

Upgrade
Daiichi Sankyo upgraded to Buy from Hold at Jefferies » 20:30
08/14/22
08/14
20:30
08/14/22
20:30
DSNKY

Daiichi Sankyo

$31.40 /

+3.94 (+14.35%)

Jefferies analyst Naoya…

Jefferies analyst Naoya Miura upgraded Daiichi Sankyo to Buy from Hold with a 4,300 yen price target.

ShowHide Related Items >><<
DSNKY Daiichi Sankyo
$31.40 /

+3.94 (+14.35%)

DSNKY Daiichi Sankyo
$31.40 /

+3.94 (+14.35%)

08/14/22 SVB Securities
Seagen price target lowered to $152 from $159 at SVB Securities
10/27/21 SVB Securities
Seagen price target raised to $200 from $190 at SVB Leerink
Downgrade
Auto Trader Group downgraded to Underweight from Neutral at JPMorgan » 20:28
08/14/22
08/14
20:28
08/14/22
20:28
ATDRY

Auto Trader Group

$1.94 /

-0.035 (-1.77%)

JPMorgan analyst Marcus…

JPMorgan analyst Marcus Diebel downgraded Auto Trader Group to Underweight from Neutral with a 596 GBp price target.

ShowHide Related Items >><<
ATDRY Auto Trader Group
$1.94 /

-0.035 (-1.77%)

06/23/22 Morgan Stanley
Auto Trader price target lowered to 730 GBp from 800 GBp at Morgan Stanley
05/27/22 Barclays
Auto Trader Group price target lowered to 660 GBp from 720 GBp at Barclays
05/27/22 Credit Suisse
Auto Trader Group price target lowered to 498 GBp from 514 GBp at Credit Suisse
05/27/22 JPMorgan
Auto Trader Group upgraded to Neutral from Underweight at JPMorgan
Upgrade
Softchoice upgraded to Outperform from Sector Perform at National Bank » 20:26
08/14/22
08/14
20:26
08/14/22
20:26
SFTC.TO

Softchoice

/

+

National Bank analyst…

National Bank analyst John Shao upgraded Softchoice to Outperform from Sector Perform with a C$28 price target.

ShowHide Related Items >><<
SFTC.TO Softchoice
/

+

06/14/22 CIBC
Softchoice downgraded to Neutral from Outperformer at CIBC
06/14/22 CIBC
Softchoice downgraded to Neutral from Outperformer at CIBC
03/08/22 Scotiabank
Softchoice upgraded to Outperform from Sector Perform at Scotiabank
01/14/22 Scotiabank
Softchoice initiated with a Sector Perform at Scotiabank
Upgrade
Plains GP Holdings upgraded to Buy from Hold at Stifel » 20:21
08/14/22
08/14
20:21
08/14/22
20:21
PAGP

Plains GP Holdings

$11.84 /

+0.13 (+1.11%)

, PAA

Plains All American

$11.68 /

+0.125 (+1.08%)

Stifel analyst Selman…

Stifel analyst Selman Akyol upgraded Plains GP Holdings (PAGP) to Buy from Hold with a price target of $16, up from $14. Plains Holdings GP, LP is a tracking stock to Plains All American Pipeline (PAA) and provides investors a 1099 option to gain exposure to PAA's K-1 tax form, noted Akyol, who also upgraded Plains All American to Buy from Hold with a price target of $16 after the company reported Q2 results above his expectations and increased its FY22 EBITDA guidance.

ShowHide Related Items >><<
PAGP Plains GP Holdings
$11.84 /

+0.13 (+1.11%)

PAA Plains All American
$11.68 /

+0.125 (+1.08%)

PAGP Plains GP Holdings
$11.84 /

+0.13 (+1.11%)

08/01/22 Seaport Global
Plains GP Holdings upgraded to Buy from Neutral at Seaport Global
08/01/22 Wolfe Research
Plains GP Holdings downgraded to Peer Perform from Outperform at Wolfe Research
07/20/22 Barclays
Plains GP Holdings price target lowered to $12 from $13 at Barclays
07/19/22 BofA
Plains All American, Plains GP upgraded to Neutral at BofA following pullback
PAA Plains All American
$11.68 /

+0.125 (+1.08%)

08/14/22 Stifel
Plains All American upgraded to Buy from Hold at Stifel
08/01/22 Seaport Global
Plains All American upgraded to Buy from Neutral at Seaport Global
08/01/22 Wolfe Research
Plains All American downgraded to Peer Perform at Wolfe Research
PAA Plains All American
$11.68 /

+0.125 (+1.08%)

PAA Plains All American
$11.68 /

+0.125 (+1.08%)

Upgrade
Plains All American upgraded to Buy from Hold at Stifel » 20:19
08/14/22
08/14
20:19
08/14/22
20:19
PAA

Plains All American

$11.68 /

+0.125 (+1.08%)

Stifel analyst Selman…

Stifel analyst Selman Akyol upgraded Plains All American to Buy from Hold with a price target of $16, up from $14, after the company reported Q2 results above his expectations and increased its FY22 EBITDA guidance. Plains has utilized a higher commodity price environment to outperform expectations in its NGL segment, said Akyol, who expresses increased confidence in higher volumes and the company's improving balance sheet.

ShowHide Related Items >><<
PAA Plains All American
$11.68 /

+0.125 (+1.08%)

PAA Plains All American
$11.68 /

+0.125 (+1.08%)

08/01/22 Seaport Global
Plains GP Holdings upgraded to Buy from Neutral at Seaport Global
08/01/22 Seaport Global
Plains All American upgraded to Buy from Neutral at Seaport Global
08/01/22 Wolfe Research
Plains All American downgraded to Peer Perform at Wolfe Research
07/20/22 Barclays
Plains All American price target lowered to $12 from $13 at Barclays
PAA Plains All American
$11.68 /

+0.125 (+1.08%)

PAA Plains All American
$11.68 /

+0.125 (+1.08%)

Recommendations
Seagen price target lowered to $152 from $159 at SVB Securities » 20:14
08/14/22
08/14
20:14
08/14/22
20:14
SGEN

Seagen

$170.27 /

-3.84 (-2.21%)

, DSNKY

Daiichi Sankyo

$31.40 /

+3.94 (+14.35%)

, MRK

Merck

$90.99 /

+2.07 (+2.33%)

SVB Securities analyst…

SVB Securities analyst Andrew Berens lowered the firm's price target on Seagen (SGEN) to $152 from $159 and keeps an Outperform rating on the shares after the company reported that an arbitrator ruled in favor of Daiichi Sankyo (DSNKY) relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate technology. He thinks the decision "comes as a surprise to most investors," but Berens adds that he believes one potential reason that Seagen shares were not down more after announcing the arbitration loss may be that investor speculation increased regarding the reported acquisition discussions being held with Merck (MRK) and the potential that this decision may clear the way for the transaction to occur.

ShowHide Related Items >><<
SGEN Seagen
$170.27 /

-3.84 (-2.21%)

MRK Merck
$90.99 /

+2.07 (+2.33%)

DSNKY Daiichi Sankyo
$31.40 /

+3.94 (+14.35%)

SGEN Seagen
$170.27 /

-3.84 (-2.21%)

07/29/22 RBC Capital
Seagen price target raised to $179 from $136 at RBC Capital
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/26/22 Piper Sandler
Seagen data provide 'some degree of de-risking,' says Piper Sandler
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
DSNKY Daiichi Sankyo
$31.40 /

+3.94 (+14.35%)

10/27/21 SVB Securities
Seagen price target raised to $200 from $190 at SVB Leerink
MRK Merck
$90.99 /

+2.07 (+2.33%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
SGEN Seagen
$170.27 /

-3.84 (-2.21%)

MRK Merck
$90.99 /

+2.07 (+2.33%)

SGEN Seagen
$170.27 /

-3.84 (-2.21%)

MRK Merck
$90.99 /

+2.07 (+2.33%)

SGEN Seagen
$170.27 /

-3.84 (-2.21%)

MRK Merck
$90.99 /

+2.07 (+2.33%)

SGEN Seagen
$170.27 /

-3.84 (-2.21%)

MRK Merck
$90.99 /

+2.07 (+2.33%)

Recommendations
Pfizer Prevnar-20 miss on co-primary endpoint could help Vaxcyte, says BofA » 20:06
08/14/22
08/14
20:06
08/14/22
20:06
PCVX

Vaxcyte

$26.35 /

+0.95 (+3.74%)

, PFE

Pfizer

$50.10 /

+1.79 (+3.71%)

BofA analyst Jason…

BofA analyst Jason Gerberry noted that Pfizer's (PFE) Prevnar-20 missed on one of the co-primary endpoints in a Phase 3 infant study, which he contends may "introduce some regulatory risk" and open up the market for higher valency vaccines like Vaxcyte's (PCVX). He assumes Pfizer's PCV20 is approved for all indications, but believes higher valency approaches, like VAX-24, still have the potential to be "highly competitive," said Gerberry, who maintains a Buy rating and $37 price target on Vaxcyte shares.

ShowHide Related Items >><<
PFE Pfizer
$50.10 /

+1.79 (+3.71%)

PCVX Vaxcyte
$26.35 /

+0.95 (+3.74%)

PCVX Vaxcyte
$26.35 /

+0.95 (+3.74%)

12/29/21 Jefferies
Vaxcyte assumed with a Buy at Jefferies
PFE Pfizer
$50.10 /

+1.79 (+3.71%)

08/12/22 JPMorgan
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
PFE Pfizer
$50.10 /

+1.79 (+3.71%)

PCVX Vaxcyte
$26.35 /

+0.95 (+3.74%)

  • 13
    Jan
PFE Pfizer
$50.10 /

+1.79 (+3.71%)

PFE Pfizer
$50.10 /

+1.79 (+3.71%)

PFE Pfizer
$50.10 /

+1.79 (+3.71%)

Recommendations
Futu Holdings price target lowered to $51.50 from $60.60 at BofA » 20:00
08/14/22
08/14
20:00
08/14/22
20:00
FUTU

Futu Holdings

$41.13 /

+0.095 (+0.23%)

BofA analyst Emma Xu…

BofA analyst Emma Xu lowered the firm's price target on Futu Holdings to $51.50 from $60.60 and keeps a Buy rating on the shares ahead of the company reporting Q2 results before the U.S. market opens on Tuesday, August 30. Futu's earnings and share price have been more correlated historically to the performance of China stocks than U.S. stocks, noted Xu, who We cut 2022-24 earnings estimates by 14%-16% to reflect the market situation.

ShowHide Related Items >><<
FUTU Futu Holdings
$41.13 /

+0.095 (+0.23%)

FUTU Futu Holdings
$41.13 /

+0.095 (+0.23%)

06/23/22 JPMorgan
Futu Holdings downgraded to Neutral after 47% rally at JPMorgan
06/23/22 JPMorgan
Futu Holdings downgraded to Neutral from Overweight at JPMorgan
06/10/22 BofA
BofA double upgrades Futu to Buy on upcoming positive developments
06/10/22 BofA
Futu Holdings upgraded to Buy from Underperform at BofA
FUTU Futu Holdings
$41.13 /

+0.095 (+0.23%)

FUTU Futu Holdings
$41.13 /

+0.095 (+0.23%)

Recommendations
MaxCyte price target raised to $11 from $10 at BTIG » 19:54
08/14/22
08/14
19:54
08/14/22
19:54
MXCT

MaxCyte

$5.86 /

+0.06 (+1.03%)

BTIG analyst Mark Massaro…

BTIG analyst Mark Massaro raised the firm's price target on MaxCyte to $11 from $10 and keeps a Buy rating on the shares following the company's "beat and raise" Q2 report. MaxCyte, unlike other tools companies, is not seeing many industry- headwinds, mainly since a lot of its business is for later-stage product development, Massaro tells investors.

ShowHide Related Items >><<
MXCT MaxCyte
$5.86 /

+0.06 (+1.03%)

MXCT MaxCyte
$5.86 /

+0.06 (+1.03%)

08/24/21
Fly Intel: Top five analyst initiations
08/24/21 Stephens
MaxCyte initiated with an Overweight at Stephens
08/24/21 William Blair
Blair starts MaxCyte at Outperform, sees 'one-of-a-kind opportunity'
08/24/21 William Blair
MaxCyte initiated with an Outperform at William Blair
MXCT MaxCyte
$5.86 /

+0.06 (+1.03%)

MXCT MaxCyte
$5.86 /

+0.06 (+1.03%)

Conference/Events
PAVmed to host business news update conference call » 16:59
08/14/22
08/14
16:59
08/14/22
16:59
PAVM

PAVmed

$2.32 /

+0.365 (+18.67%)

Chairman & CEO Aklog…

Chairman & CEO Aklog and CFO McGrath hold a business news update conference call to be held on August 16 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
PAVM PAVmed
$2.32 /

+0.365 (+18.67%)

PAVM PAVmed
$2.32 /

+0.365 (+18.67%)

04/07/22 Maxim
PAVmed price target lowered to $4 from $10 at Maxim
02/10/22 Cantor Fitzgerald
PAVmed assumed with an Overweight at Cantor Fitzgerald
PAVM PAVmed
$2.32 /

+0.365 (+18.67%)

Hot Stocks
Plus Therapeutics presents data from Ongoing ReSPECT trials » 13:26
08/14/22
08/14
13:26
08/14/22
13:26
PSTV

Plus Therapeutics

/

+

Plus Therapeutics…

Plus Therapeutics announced it presented "positive" data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome, or 186RNL, in the treatment of recurrent glioblastoma, or GBM, and leptomeningeal metastases, or LM, at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. The conference, co-sponsored by the Society for Neuro-Oncology and the American Society of Clinical Oncology, is being held August 12-13 in Toronto, Canada. Data show 186RNL treatment is safe and well-tolerated, with no adverse events with outcome of death or discontinuations. At the time of the presentation, four patients remain alive. Cohort 7 of the trial, with an increased dose of 186RNL is currently enrolling. "While we can draw only limited conclusions from the first patient cohort, these findings suggest that the application of locally delivered and highly targeted 186RNL for the treatment of LM has the potential to be an effective and safe treatment for patients," stated Norman LaFrance, M.D., Chief Medical Officer and SVP at Plus Therapeutics. "Taken together, these data from both ReSPECT-LM and ReSPECT-GBM represent Plus' ongoing dedication to evaluating 186RNL in clinical settings and the encouraging results showing our product is safe and effective in treating these difficult-to-treat cancers. As we look ahead to the rest of 2022, we remain focused on completing key manufacturing, clinical and regulatory milestones that will support the further development and validation of 186RNL so we can quickly bring our therapy to patients," added Marc Hedrick, M.D., President and CEO of Plus Therapeutics.

ShowHide Related Items >><<
PSTV Plus Therapeutics
/

+

PSTV Plus Therapeutics
/

+

07/22/22 H.C. Wainwright
Plus Therapeutics price target lowered to $3.50 from $7 at H.C. Wainwright
Periodicals
Affirm CEO says next recession will silence doubters, WSJ reports » 15:08
08/13/22
08/13
15:08
08/13/22
15:08
AFRM

Affirm

$39.20 /

+2.22 (+6.00%)

Max Levchin says the…

Max Levchin says the market is wrong about Affirm Holdings, the buy now, pay later company he co-founded a decade ago, and it might just take a recession to prove it, The Wall Street Journal's AnnaMaria Andriotis reports. Affirm's stock is down 77% since hitting its peak in November, compared with a 9% decline in the S&P 500 during the same period, as investors worry about future costs of borrowing, growing competition and whether Affirm's borrowers will fall behind on payments during a downturn, the author notes. Levchin is confident that Affirm has safely cracked the code to underwriting more consumers than banks would. Reference Link

ShowHide Related Items >><<
AFRM Affirm
$39.20 /

+2.22 (+6.00%)

AFRM Affirm
$39.20 /

+2.22 (+6.00%)

08/11/22 BofA
Affirm price target raised to $45 from $39 at BofA
07/14/22 Stephens
Amazon's record Prime Day likely to benefit Affirm GMV, says Stephens
07/10/22 Goldman Sachs
Affirm initiated with a Neutral at Goldman Sachs
06/29/22 Piper Sandler
Affirm price target lowered to $28 from $32 at Piper Sandler
AFRM Affirm
$39.20 /

+2.22 (+6.00%)

AFRM Affirm
$39.20 /

+2.22 (+6.00%)

AFRM Affirm
$39.20 /

+2.22 (+6.00%)

AFRM Affirm
$39.20 /

+2.22 (+6.00%)

Periodicals
Victoria's Secret is trying a new look, many customers not aware, WSJ reports » 15:05
08/13/22
08/13
15:05
08/13/22
15:05
VSCO

Victoria's Secret

$40.59 /

+1.62 (+4.16%)

Victoria's Secret…

Victoria's Secret spent the last year trying to shift from a brand associated with the male gaze to a company representing female empowerment, but many customers don't know it made any changes at all, The Wall Street Journal's Khadeeja Safdar reports. Most shoppers who participated in a study conducted by the lingerie seller in February weren't able to identify Victoria's Secret & Co. as the brand behind recent ads of models wearing its lingerie, according to internal research documents reviewed by The Wall Street Journal. The ads show women with different ethnicities, body types and ages mostly in natural-looking lingerie, the author notes. Reference Link

ShowHide Related Items >><<
VSCO Victoria's Secret
$40.59 /

+1.62 (+4.16%)

VSCO Victoria's Secret
$40.59 /

+1.62 (+4.16%)

08/01/22 Cowen
Cowen starts Victoria's Secret at Market Perform, cautious on second half
08/01/22 Cowen
Victoria's Secret initiated with a Market Perform at Cowen
07/15/22 UBS
Victoria's Secret price target lowered to $31 from $49 at UBS
06/06/22 UBS
Victoria's Secret price target lowered to $49 from $59 at UBS
VSCO Victoria's Secret
$40.59 /

+1.62 (+4.16%)

VSCO Victoria's Secret
$40.59 /

+1.62 (+4.16%)

VSCO Victoria's Secret
$40.59 /

+1.62 (+4.16%)

Hot Stocks
Plus Therapeutics presents data from Oongoing ReSPECT clinical trials » 15:01
08/13/22
08/13
15:01
08/13/22
15:01
PSTV

Plus Therapeutics

/

+

Plus Therapeutics…

Plus Therapeutics presented data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome, in the treatment of recurrent glioblastoma and le The oral presentation, titled Safety and Feasibility of Rhenium-186 Nanoliposome in Leptomeningeal Metastases Phase 1/2a Dose Escalation Trial, demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1. Furthermore, all three patients in the cohort were observed to have prompt and complete 186RNL distribution throughout the cerebrospinal fluid subarachnoid space that was durable past one week and very well tolerated. Importantly, all patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92% which was also durable. Another a poster titled, Safety and Feasibility of Rhenium-186 NanoLiposome in Recurrent Glioma: the ReSPECT Phase 1 Trial, demonstrated that in 23 subjects with recurrent GBM receiving a single administration of 186RNL, significant overall survival benefits were observed in those achieving an average absorbed radiation dose greater than 100 Gy to the tumor compared to those with less absorption. These findings suggest a correlation in increasing convected drug volume and radiation dose with improvement in overall survival of patients and to date, 80% of patients in cohorts 5-7 met the threshold of high levels of absorption greater than 100 Gy. Data show 186RNL treatment is safe and well-tolerated, with no adverse events with outcome of death or discontinuations. At the time of the presentation, four patients remain alive. Cohort 7 of the trial, with an increased dose of 186RNL, is currently enrolling.

ShowHide Related Items >><<
PSTV Plus Therapeutics
/

+

PSTV Plus Therapeutics
/

+

07/22/22 H.C. Wainwright
Plus Therapeutics price target lowered to $3.50 from $7 at H.C. Wainwright
Periodicals
Coinbase looking more like a meme stock, Barron's says » 09:48
08/13/22
08/13
09:48
08/13/22
09:48
COIN

Coinbase

$90.47 /

+6.49 (+7.73%)

, GME

GameStop

$40.71 /

+1.2 (+3.04%)

, AMC

AMC Entertainment

$24.39 /

-1.045 (-4.11%)

Coinbase (COIN) trades…

Coinbase (COIN) trades like a side bet on Bitcoin. Lately, though, shares of the crypto brokerage have added meme-stock volatility to the mix, taking cues from the likes of GameStop (GME) and AMC Entertainment (AMC), Joe Light writes in this week's edition of Barron's. Coinbase's volatility arises from several factors. For one, hordes of investors are betting against it. About 18% of Coinbase stock is sold short, the author notes. Such high short interest makes a stock vulnerable to a "squeeze," when traders who had sold borrowed shares - aiming to buy them back later at a lower price - must frantically cover their positions, causing a stock to surge. This helps Coinbase trade untethered from its fundamentals, acting like meme stocks such as AMC and GameStop, both heavily shorted and unmoored from valuation measures like price/earnings ratios, the publication adds. Reference Link

ShowHide Related Items >><<
GME GameStop
$40.71 /

+1.2 (+3.04%)

COIN Coinbase
$90.47 /

+6.49 (+7.73%)

AMC AMC Entertainment
$24.39 /

-1.045 (-4.11%)

COIN Coinbase
$90.47 /

+6.49 (+7.73%)

08/11/22 DA Davidson
Coinbase price target raised to $100 from $90 at DA Davidson
08/10/22 BTIG
Coinbase price target lowered to $220 from $290 at BTIG
08/10/22 Compass Point
Coinbase price target lowered to $95 from $100 at Compass Point
08/10/22 JPMorgan
Coinbase price target raised to $64 from $61 at JPMorgan
GME GameStop
$40.71 /

+1.2 (+3.04%)

07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
05/26/22 Wedbush
Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns
03/28/22 B. Riley
Bed Bath & Beyond price target raised to $26 from $19 at B. Riley
03/18/22 Wedbush
GameStop price target lowered to $30 from $45 at Wedbush
AMC AMC Entertainment
$24.39 /

-1.045 (-4.11%)

07/07/22 Citi
AMC Entertainment price target lowered to $5 from $6 at Citi
06/21/22 B. Riley
AMC Entertainment price target lowered to $11 from $16 at B. Riley
06/06/22 Citi
AMC Entertainment shares remain overvalued, says Citi
05/03/22 B. Riley
B. Riley sees AMC-like capital raise path for Redbox
GME GameStop
$40.71 /

+1.2 (+3.04%)

COIN Coinbase
$90.47 /

+6.49 (+7.73%)

AMC AMC Entertainment
$24.39 /

-1.045 (-4.11%)

GME GameStop
$40.71 /

+1.2 (+3.04%)

COIN Coinbase
$90.47 /

+6.49 (+7.73%)

AMC AMC Entertainment
$24.39 /

-1.045 (-4.11%)

GME GameStop
$40.71 /

+1.2 (+3.04%)

COIN Coinbase
$90.47 /

+6.49 (+7.73%)

AMC AMC Entertainment
$24.39 /

-1.045 (-4.11%)

GME GameStop
$40.71 /

+1.2 (+3.04%)

COIN Coinbase
$90.47 /

+6.49 (+7.73%)

AMC AMC Entertainment
$24.39 /

-1.045 (-4.11%)

Periodicals
Best-run auto insurer Progressive may not be best stock to buy, Barron's says » 09:43
08/13/22
08/13
09:43
08/13/22
09:43
PGR

Progressive

$121.74 /

+1.31 (+1.09%)

American drivers are back…

American drivers are back on the road despite high gas prices, and miles driven are now above pre-pandemic levels. That's bad news for auto insurers, which are reporting some of their worst results in a decade due to elevated claims expenses, Andrew Bary writes in this week's edition of Barron's. Progressive, the No. 3 auto insurer based on premium revenue, continues to distance itself from rivals and take market share, the author notes. But auto insurance costs were up 1.3% in July after rising 1.9% in June, based on the consumer price index. More increases are likely as the industry deals with what Mercury General has termed "extraordinarily high inflation" in claims costs. Reference Link

ShowHide Related Items >><<
PGR Progressive
$121.74 /

+1.31 (+1.09%)

PGR Progressive
$121.74 /

+1.31 (+1.09%)

07/18/22 MKM Partners
Progressive price target raised to $135 from $125 at MKM Partners
07/12/22 Jefferies
Progressive price target raised to $125 from $106 at Jefferies
06/23/22 Keefe Bruyette
Progressive upgraded to Market Perform on rate increases at Keefe Bruyette
06/23/22 Keefe Bruyette
Progressive upgraded to Market Perform from Underperform at Keefe Bruyette
PGR Progressive
$121.74 /

+1.31 (+1.09%)

PGR Progressive
$121.74 /

+1.31 (+1.09%)

Periodicals
Good time to buy stock in Buffet's Berkshire Hathaway, Barron's says » 09:40
08/13/22
08/13
09:40
08/13/22
09:40
BRK.B

Berkshire Hathaway

$301.50 /

+5.14 (+1.73%)

, BRK.A

Berkshire Hathaway

$452,000.00 /

+7089.43 (+1.59%)

Berkshire Hathaway has…

Berkshire Hathaway has never been in better shape. Its stock looks appealing after pulling back more than 15% from its record high in March, Andrew Bary writes in this week's edition of Barron's. The conglomerate's operating profits were up 22% in the second quarter, excluding foreign-exchange gains, powered by a 56% gain in investment income. Berkshire's annual operating income is running at more than $30 billion after taxes, the author notes. Reference Link

ShowHide Related Items >><<
BRK.B Berkshire Hathaway
$301.50 /

+5.14 (+1.73%)

BRK.A Berkshire Hathaway
$452,000.00 /

+7089.43 (+1.59%)

BRK.B Berkshire Hathaway
$301.50 /

+5.14 (+1.73%)

06/23/22 Truist
Truist ups Occidental target to 'Street high' $93, sees good odds of Buffett bid
05/01/22 Keefe Bruyette
Berkshire price target lowered to $560,000 from $565,000 at Keefe Bruyette
11/07/21 Keefe Bruyette
Berkshire Q3 missed 'virtually across the board,' says Keefe Bruyette
09/07/21 Wells Fargo
Kroger price target raised to $46 from $39 at Wells Fargo
BRK.A Berkshire Hathaway
$452,000.00 /

+7089.43 (+1.59%)

08/07/22 Keefe Bruyette
Berkshire price target raised to $535,000 from $480,000 at Keefe Bruyette
04/20/22 Keefe Bruyette
Alleghany downgraded to Market Perform from Outperform at Keefe Bruyette
BRK.B Berkshire Hathaway
$301.50 /

+5.14 (+1.73%)

BRK.B Berkshire Hathaway
$301.50 /

+5.14 (+1.73%)

BRK.B Berkshire Hathaway
$301.50 /

+5.14 (+1.73%)

BRK.A Berkshire Hathaway
$452,000.00 /

+7089.43 (+1.59%)

Periodicals
Royal Caribbean among companies at risk of liquidity squeeze, Barron's says » 09:38
08/13/22
08/13
09:38
08/13/22
09:38
RCL

Royal Caribbean

$42.36 /

+0.655 (+1.57%)

, BBBY

Bed Bath & Beyond

$12.95 /

+2.34 (+22.05%)

, PRTY

Party City

$1.39 /

-0.005 (-0.36%)

, RAD

Rite Aid

$11.04 /

+0.45 (+4.25%)

, WWW

Wolverine World Wide

$22.91 /

+0.19 (+0.84%)

, CAL

Caleres

$29.65 /

-0.16 (-0.54%)

, EXPR

Express

$2.18 /

+0.085 (+4.06%)

Rising interest rates and…

Rising interest rates and tightening credit conditions could spell trouble for higher-risk issuers that need to refinance debt or borrow more, Evie Lu writes in this week's edition of Barron's. Among those are Royal Caribbean (RCL), Bed Bath & Beyond (BBBY), Party City (PRTY), Rite Aid (RAD), Wolverine World Wide (WWW), Caleres (CAL), and Express (EXPR), the author says. Reference Link

ShowHide Related Items >><<
WWW Wolverine World Wide
$22.91 /

+0.19 (+0.84%)

RCL Royal Caribbean
$42.36 /

+0.655 (+1.57%)

RAD Rite Aid
$11.04 /

+0.45 (+4.25%)

PRTY Party City
$1.39 /

-0.005 (-0.36%)

EXPR Express
$2.18 /

+0.085 (+4.06%)

CAL Caleres
$29.65 /

-0.16 (-0.54%)

BBBY Bed Bath & Beyond
$12.95 /

+2.34 (+22.05%)

RCL Royal Caribbean
$42.36 /

+0.655 (+1.57%)

07/29/22 Wells Fargo
Royal Caribbean price target lowered to $58 from $81 at Wells Fargo
07/29/22 Deutsche Bank
Royal Caribbean price target lowered to $48 from $50 at Deutsche Bank
07/29/22 Susquehanna
Royal Caribbean price target lowered to $50 from $70 at Susquehanna
06/29/22 Barclays
Barclays initiates cruise line space with Royal Caribbean top pick
BBBY Bed Bath & Beyond
$12.95 /

+2.34 (+22.05%)

08/09/22 Baird
Baird downgrades Bed Bath & Beyond to sell after 86% two-day rally
08/09/22 Baird
Bed Bath & Beyond downgraded to Underperform from Neutral at Baird
08/08/22 Odeon Capital
Bed Bath & Beyond cut to Hold at Odeon Capital following doubling in a week
08/08/22 Odeon Capital
Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
PRTY Party City
$1.39 /

-0.005 (-0.36%)

RAD Rite Aid
$11.04 /

+0.45 (+4.25%)

06/03/22 Deutsche Bank
Rite Aid price target raised to $4 from $2 at Deutsche Bank
04/21/22 Deutsche Bank
Deutsche Bank says 'just stop' with the Rite Aid takeover talk
04/18/22 Deutsche Bank
Rite Aid price target raised to $2 from $1 at Deutsche Bank
04/07/22 Deutsche Bank
Deutsche downgrades Rite Aid to Sell with $1 target into Q4 results
WWW Wolverine World Wide
$22.91 /

+0.19 (+0.84%)

07/25/22 Piper Sandler
Wolverine World Wide assumed with an Overweight at Piper Sandler
07/25/22 Williams Trading
Wolverine World Wide downgraded to Hold from Buy at Williams Trading
07/20/22 Stifel
Stifel downgrades trio of Sports and Lifestyle Brands to Hold
07/20/22 Stifel
Wolverine World Wide downgraded to Hold from Buy at Stifel
CAL Caleres
$29.65 /

-0.16 (-0.54%)

06/24/22 Seaport Global
Caleres initiated with a Buy at Seaport Global
01/11/22 Loop Capital
Loop Capital upgrades Steven Madden to Buy after positive news from peers
11/19/21 Loop Capital
Caleres price target raised to $40 from $35 at Loop Capital
09/07/21 Loop Capital
Caleres price target raised to $35 from $30 at Loop Capital
EXPR Express
$2.18 /

+0.085 (+4.06%)

WWW Wolverine World Wide
$22.91 /

+0.19 (+0.84%)

RCL Royal Caribbean
$42.36 /

+0.655 (+1.57%)

RAD Rite Aid
$11.04 /

+0.45 (+4.25%)

PRTY Party City
$1.39 /

-0.005 (-0.36%)

EXPR Express
$2.18 /

+0.085 (+4.06%)

CAL Caleres
$29.65 /

-0.16 (-0.54%)

BBBY Bed Bath & Beyond
$12.95 /

+2.34 (+22.05%)

RCL Royal Caribbean
$42.36 /

+0.655 (+1.57%)

RAD Rite Aid
$11.04 /

+0.45 (+4.25%)

BBBY Bed Bath & Beyond
$12.95 /

+2.34 (+22.05%)

WWW Wolverine World Wide
$22.91 /

+0.19 (+0.84%)

RCL Royal Caribbean
$42.36 /

+0.655 (+1.57%)

RAD Rite Aid
$11.04 /

+0.45 (+4.25%)

PRTY Party City
$1.39 /

-0.005 (-0.36%)

EXPR Express
$2.18 /

+0.085 (+4.06%)

CAL Caleres
$29.65 /

-0.16 (-0.54%)

BBBY Bed Bath & Beyond
$12.95 /

+2.34 (+22.05%)

RCL Royal Caribbean
$42.36 /

+0.655 (+1.57%)

RAD Rite Aid
$11.04 /

+0.45 (+4.25%)

PRTY Party City
$1.39 /

-0.005 (-0.36%)

EXPR Express
$2.18 /

+0.085 (+4.06%)

CAL Caleres
$29.65 /

-0.16 (-0.54%)

BBBY Bed Bath & Beyond
$12.95 /

+2.34 (+22.05%)

Periodicals
American Eagle stock set to rise again, Barron's says » 09:28
08/13/22
08/13
09:28
08/13/22
09:28
AEO

American Eagle

$12.84 /

+0.38 (+3.05%)

Things admittedly have…

Things admittedly have been challenging for American Eagle, Karishma Vanjani writes in this week's edition of Barron's. Still, the stock has believers who say the issues highlighted in the earnings call were temporary and that the company has solutions for the long run. The valuation-at about $2 billion, American Eagle is a small-cap stock-has fallen to a level that likely reflects the worst of the impact, the author adds. Reference Link

ShowHide Related Items >><<
AEO American Eagle
$12.84 /

+0.38 (+3.05%)

AEO American Eagle
$12.84 /

+0.38 (+3.05%)

08/01/22 Cowen
American Eagle downgraded to Market Perform from Outperform at Cowen
07/26/22 Deutsche Bank
Walmart outlook 'red flag for apparel,' says Deutsche Bank
07/26/22 BofA
American Eagle downgraded to Underperform at BofA on near-term pressures
07/26/22 BofA
American Eagle downgraded to Underperform from Neutral at BofA
AEO American Eagle
$12.84 /

+0.38 (+3.05%)

AEO American Eagle
$12.84 /

+0.38 (+3.05%)

AEO American Eagle
$12.84 /

+0.38 (+3.05%)

Periodicals
Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says » 09:14
08/13/22
08/13
09:14
08/13/22
09:14
LLY

Eli Lilly

$307.97 /

+7.72 (+2.57%)

, NVO

Novo Nordisk

$107.43 /

-0.7864 (-0.73%)

New weight-loss drugs,…

New weight-loss drugs, known as incretins, from Eli Lilly (LLY) and Novo Nordisk (NVO) have show striking results in studies. If insurers step up to back them, the drugs - and the stocks - could take off, Bill Alpert writes in this week's edition of Barron's. If every hefty American got treated at these drugs' current prices, the annual market for incretins would be a trillion dollars. Insurers can't afford that, of course, and access to the new drugs is highly restricted. But there's plenty of room for prices to come down and still reward Novo and Lilly shareholders, the author notes. Reference Link

ShowHide Related Items >><<
NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

08/11/22 Raymond James
ProQR upgraded to Outperform at Raymond James on RNA editing 'conviction'
08/05/22 Morgan Stanley
Eli Lilly recent weakness a buying opportunity, says Morgan Stanley
08/01/22 Jefferies
Concert Pharmaceuticals price target raised to $14 from $9.50 at Jefferies
07/27/22 Benchmark
AbCellera collaboration lowers reliance on Lilly, says Benchmark
NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/04/22 Barclays
Novo Nordisk price target lowered to DKK 825 from DKK 875 at Barclays
08/03/22 Piper Sandler
Piper says Altimmune selloff related to Novo continuing Phase 3 SELECT trial
07/15/22 Morgan Stanley
Novo Nordisk upgraded to Overweight from Equal Weight at Morgan Stanley
NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

Periodicals
Plug Power, Sunrun among stocks for rush to renewable energy, Barron's says » 09:07
08/13/22
08/13
09:07
08/13/22
09:07
AES

AES Corp.

$24.88 /

+0.535 (+2.20%)

, BE

Bloom Energy

$30.43 /

+1.205 (+4.12%)

, FCX

Freeport-McMoRan

$31.61 /

-0.055 (-0.17%)

, PLUG

Plug Power

$29.54 /

+1.8 (+6.49%)

, RUN

Sunrun

$36.12 /

+0.6 (+1.69%)

The climate bill in the…

The climate bill in the U.S., approved by Congress this past week and sent to President Biden, unlocks $370 billion for clean-energy incentives and consumer benefits, Avi Salzman writes in this week's edition of Barron's. Barron's has identified six promising companies and stocks, including a developer of solar roof projects, two innovators in hydrogen technology, a battery maker, a supplier of green power to utility companies, and a miner of a mineral key to renewables. According to the publication, AES (AES), Bloom Energy (BE), Freeport-McMoRan (FCX), LG Energy Solution, Plug Power (PLUG) and Sunrun (RUN) could make the most of the new opportunities in renewables. Reference Link

ShowHide Related Items >><<
RUN Sunrun
$36.12 /

+0.6 (+1.69%)

PLUG Plug Power
$29.54 /

+1.8 (+6.49%)

FCX Freeport-McMoRan
$31.61 /

-0.055 (-0.17%)

BE Bloom Energy
$30.43 /

+1.205 (+4.12%)

AES AES Corp.
$24.88 /

+0.535 (+2.20%)

AES AES Corp.
$24.88 /

+0.535 (+2.20%)

07/01/22 Morgan Stanley
Southeast Asia solar panels should keep flowing to U.S., says Morgan Stanley
05/10/22 Susquehanna
AES Corp. price target lowered to $30 from $32 at Susquehanna
04/25/22 Credit Suisse
AES Corp. initiated with a Neutral at Credit Suisse
03/22/22 Citi
AES Corp. initiated with a Buy at Citi
BE Bloom Energy
$30.43 /

+1.205 (+4.12%)

08/11/22 BMO Capital
Bloom Energy price target raised to $29 from $20 at BMO Capital
08/11/22 Truist
Bloom Energy price target raised to $31 from $19 at Truist
08/10/22 Raymond James
Bloom Energy price target raised to $29 from $23 at Raymond James
08/10/22 Susquehanna
Bloom Energy price target raised to $30 from $28 at Susquehanna
FCX Freeport-McMoRan
$31.61 /

-0.055 (-0.17%)

07/22/22 Deutsche Bank
Freeport-McMoRan price target lowered to $35 from $37 at Deutsche Bank
07/22/22 RBC Capital
Freeport-McMoRan price target lowered to $35 from $46 at RBC Capital
07/22/22 Citi
Freeport-McMoRan price target raised to $29 from $28 at Citi
07/19/22 Barclays
Freeport-McMoRan price target lowered to $24 from $29 at Barclays
PLUG Plug Power
$29.54 /

+1.8 (+6.49%)

08/12/22 Wells Fargo
Plug Power price target raised to $29 from $19 at Wells Fargo
08/11/22 Citi
Plug Power price target raised to $36 from $20 at Citi
08/11/22 Truist
Plug Power price target raised to $32 from $21 at Truist
08/10/22 B. Riley
Plug Power price target raised to $32 from $31 at B. Riley
RUN Sunrun
$36.12 /

+0.6 (+1.69%)

08/08/22 JPMorgan
Sunrun price target raised to $65 from $52 at JPMorgan
08/04/22 Barclays
Sunrun initiated with an Overweight at Barclays
08/04/22 Evercore ISI
Sunrun price target raised to $67 from $64 at Evercore ISI
08/04/22 Piper Sandler
Sunrun price target raised to $30 from $29 at Piper Sandler
RUN Sunrun
$36.12 /

+0.6 (+1.69%)

PLUG Plug Power
$29.54 /

+1.8 (+6.49%)

FCX Freeport-McMoRan
$31.61 /

-0.055 (-0.17%)

BE Bloom Energy
$30.43 /

+1.205 (+4.12%)

AES AES Corp.
$24.88 /

+0.535 (+2.20%)

RUN Sunrun
$36.12 /

+0.6 (+1.69%)

AES AES Corp.
$24.88 /

+0.535 (+2.20%)

RUN Sunrun
$36.12 /

+0.6 (+1.69%)

PLUG Plug Power
$29.54 /

+1.8 (+6.49%)

FCX Freeport-McMoRan
$31.61 /

-0.055 (-0.17%)

BE Bloom Energy
$30.43 /

+1.205 (+4.12%)

RUN Sunrun
$36.12 /

+0.6 (+1.69%)

PLUG Plug Power
$29.54 /

+1.8 (+6.49%)

FCX Freeport-McMoRan
$31.61 /

-0.055 (-0.17%)

BE Bloom Energy
$30.43 /

+1.205 (+4.12%)

AES AES Corp.
$24.88 /

+0.535 (+2.20%)

On The Fly
Opening Day: Treasure Global latest to surge following small IPO » 08:56
08/13/22
08/13
08:56
08/13/22
08:56
HKD

AMTD Digital

$198.00 /

-12 (-5.71%)

, MEGL

Magic Empire Global

$8.20 /

-2.6 (-24.07%)

, FRZA

Forza X1

$7.37 /

-5.63 (-43.31%)

, REBN

Reborn Coffee

$4.87 /

-4.16 (-46.07%)

, CHG

Corphousing

$3.73 /

-0.555 (-12.95%)

, TGL

Treasure Global

$8.41 /

-9.29 (-52.49%)

, HMAC

Hainan Manaslu Acquisition

/

+

, EMCG

Embrace Change Acquisition

$19.87 /

+ (+0.00%)

, VRAX

Virax Biolabs

$6.77 /

-0.16 (-2.31%)

, STBX

Starbox

/

+

, GCT

GigaCloud

/

+

, BITD

Bitdefender

/

+

, AMZN

Amazon.com

$143.55 /

+2.935 (+2.09%)

, UBER

Uber

$32.47 /

+0.23 (+0.71%)

, DASH

DoorDash

$77.35 /

-0.59 (-0.76%)

Shares of Malaysian…

ShowHide Related Items >><<
VRAX Virax Biolabs
$6.77 /

-0.16 (-2.31%)

UBER Uber
$32.47 /

+0.23 (+0.71%)

TGL Treasure Global
$8.41 /

-9.29 (-52.49%)

MEGL Magic Empire Global
$8.20 /

-2.6 (-24.07%)

HKD AMTD Digital
$198.00 /

-12 (-5.71%)

DASH DoorDash
$77.35 /

-0.59 (-0.76%)

AMZN Amazon.com
$143.55 /

+2.935 (+2.09%)

HKD AMTD Digital
$198.00 /

-12 (-5.71%)

MEGL Magic Empire Global
$8.20 /

-2.6 (-24.07%)

FRZA Forza X1
$7.37 /

-5.63 (-43.31%)

REBN Reborn Coffee
$4.87 /

-4.16 (-46.07%)

CHG Corphousing
$3.73 /

-0.555 (-12.95%)

TGL Treasure Global
$8.41 /

-9.29 (-52.49%)

HMAC Hainan Manaslu Acquisition
/

+

EMCG Embrace Change Acquisition
$19.87 /

+ (+0.00%)

VRAX Virax Biolabs
$6.77 /

-0.16 (-2.31%)

STBX Starbox
/

+

GCT GigaCloud
/

+

BITD Bitdefender
/

+

AMZN Amazon.com
$143.55 /

+2.935 (+2.09%)

08/11/22 Craig-Hallum
Kornit Digital price target raised to $32 from $26 at Craig-Hallum
08/10/22 Macquarie
Macquarie started Coupang at Outperform with $26 target yesterday
08/10/22 Oppenheimer
Trade Desk price target raised to $78 from $60 at Oppenheimer
08/08/22 B. Riley
B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
UBER Uber
$32.47 /

+0.23 (+0.71%)

08/05/22 Wedbush
Uber's June quarter a step in the right direction, says Wedbush
08/03/22 MKM Partners
Uber price target raised to $40 from $32 at MKM Partners
08/03/22 Truist
Uber price target raised to $67 from $62 at Truist
08/03/22 Evercore ISI
Uber price target raised to $75 from $69 at Evercore ISI
DASH DoorDash
$77.35 /

-0.59 (-0.76%)

08/05/22 Needham
DoorDash price target raised to $115 from $100 at Needham
08/05/22 RBC Capital
DoorDash price target raised to $100 from $94 at RBC Capital
08/05/22 Evercore ISI
DoorDash price target raised to $122 from $98 at Evercore ISI
08/05/22 Barclays
DoorDash price target raised to $90 from $80 at Barclays
UBER Uber
$32.47 /

+0.23 (+0.71%)

DASH DoorDash
$77.35 /

-0.59 (-0.76%)

AMZN Amazon.com
$143.55 /

+2.935 (+2.09%)

  • 12
    Aug
  • 12
    Aug
  • 12
    Aug
  • 05
    Aug
  • 12
    Aug
  • 14
    Jul
  • 21
    Jul
  • 19
    Aug
  • 15
    Jul
UBER Uber
$32.47 /

+0.23 (+0.71%)

HKD AMTD Digital
$198.00 /

-12 (-5.71%)

DASH DoorDash
$77.35 /

-0.59 (-0.76%)

AMZN Amazon.com
$143.55 /

+2.935 (+2.09%)

UBER Uber
$32.47 /

+0.23 (+0.71%)

REBN Reborn Coffee
$4.87 /

-4.16 (-46.07%)

HKD AMTD Digital
$198.00 /

-12 (-5.71%)

FRZA Forza X1
$7.37 /

-5.63 (-43.31%)

DASH DoorDash
$77.35 /

-0.59 (-0.76%)

AMZN Amazon.com
$143.55 /

+2.935 (+2.09%)

UBER Uber
$32.47 /

+0.23 (+0.71%)

DASH DoorDash
$77.35 /

-0.59 (-0.76%)

AMZN Amazon.com
$143.55 /

+2.935 (+2.09%)

Conference/Events
Hologic participates in a conference call with JPMorgan » 00:28
08/13/22
08/13
00:28
08/13/22
00:28
HOLX

Hologic

$72.98 /

+0.94 (+1.30%)

JPMorgan Life Science…

JPMorgan Life Science Tools & Diagnostics Analyst Woodring holds a conference call with CEO MacMillan on August 16 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
HOLX Hologic
$72.98 /

+0.94 (+1.30%)

HOLX Hologic
$72.98 /

+0.94 (+1.30%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$72.98 /

+0.94 (+1.30%)

HOLX Hologic
$72.98 /

+0.94 (+1.30%)

Conference/Events
JPMorgan ai/surface transport analyst to hold analyst/industry conference call » 00:24
08/13/22
08/13
00:24
08/13/22
00:24

Airfreight & Surface…

Airfreight & Surface Transportation Analyst Ossenbeck and European Transports & Logistics Analyst Bland, along with Founder & CEO Schreiber of Freightos, provide an ocean and airfreight update on an Analyst/Industry conference call to be held on August 16 at 10 am.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.